Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P15907

UPID:
SIAT1_HUMAN

ALTERNATIVE NAMES:
B-cell antigen CD75; CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1; ST6Gal I; Sialyltransferase 1

ALTERNATIVE UPACC:
P15907; A8KA14; B2R513; D3DNV3

BACKGROUND:
The enzyme Beta-galactoside alpha-2,6-sialyltransferase 1, also referred to as ST6Gal I or Sialyltransferase 1, is integral to the biosynthesis of sialoglycoconjugates. By transferring sialic acid to galactose-containing substrates, it influences the structural diversity and function of glycoproteins and glycolipids, which are essential for cell-cell communication.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Beta-galactoside alpha-2,6-sialyltransferase 1 holds promise for unveiling novel therapeutic avenues. Its critical role in the synthesis of sialoglycoconjugates positions it as a potential target in the development of treatments for diseases where glycoprotein and glycolipid function is compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.